SLA2

Summary

SLA2 (Src like adaptor 2, HGNC:17329) is a protein-coding gene on chromosome 20q11.23, encoding Src-like-adapter 2 (Q9H6Q3). Adapter protein, which negatively regulates T-cell receptor (TCR) signaling.

This gene encodes a member of the SLAP family of adapter proteins. The encoded protein may play an important receptor-proximal role in downregulating T and B cell-mediated responses and inhibits antigen receptor-induced calcium mobilization. This protein interacts with Cas-Br-M (murine) ecotropic retroviral transforming sequence c. Two transcript variants encoding distinct isoforms have been identified for this gene.

Source: NCBI Gene 84174 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 49 total
• MANE Select transcript: NM_032214

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17329
Approved symbol	SLA2
Name	Src like adaptor 2
Location	20q11.23
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21992, SLAP-2
Ensembl gene	ENSG00000101082
Ensembl biotype	protein_coding
OMIM	606577
Entrez	84174

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000262866, ENST00000360672, ENST00000876805, ENST00000876806, ENST00000948638, ENST00000948639

RefSeq mRNA: 2 — MANE Select: NM_032214 NM_032214, NM_175077

CCDS: CCDS13282, CCDS13283

Canonical transcript exons

ENST00000262866 — 8 exons

Exon	Start	End
ENSE00000661775	36632595	36632698
ENSE00000661776	36615225	36615374
ENSE00000661777	36614305	36614437
ENSE00000800424	36633543	36633629
ENSE00000800425	36634490	36634589
ENSE00001290193	36645837	36646196
ENSE00001388358	36641245	36641378
ENSE00001894282	36612318	36613986

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 91.62.

FANTOM5 (CAGE): breadth broad, TPM avg 5.8716 / max 260.4362, expressed in 246 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187127	5.8716	246

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	91.62	gold quality
granulocyte	CL:0000094	88.99	gold quality
leukocyte	CL:0000738	88.57	gold quality
monocyte	CL:0000576	88.50	gold quality
blood	UBERON:0000178	87.64	gold quality
ileal mucosa	UBERON:0000331	82.55	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.95	gold quality
lymph node	UBERON:0000029	77.67	gold quality
oviduct epithelium	UBERON:0004804	76.79	gold quality
spleen	UBERON:0002106	75.04	gold quality
vermiform appendix	UBERON:0001154	74.93	gold quality
superficial temporal artery	UBERON:0001614	74.66	silver quality
oocyte	CL:0000023	73.80	silver quality
bone marrow cell	CL:0002092	73.77	gold quality
bone marrow	UBERON:0002371	73.62	gold quality
nasal cavity epithelium	UBERON:0005384	71.98	gold quality
amniotic fluid	UBERON:0000173	71.88	gold quality
secondary oocyte	CL:0000655	70.23	silver quality
caecum	UBERON:0001153	70.08	gold quality
right lung	UBERON:0002167	69.84	gold quality
thymus	UBERON:0002370	69.55	gold quality
colonic epithelium	UBERON:0000397	69.10	gold quality
gall bladder	UBERON:0002110	68.26	gold quality
cardiac muscle of right atrium	UBERON:0003379	68.00	gold quality
left ventricle myocardium	UBERON:0006566	67.69	gold quality
tibialis anterior	UBERON:0001385	66.84	silver quality
upper lobe of left lung	UBERON:0008952	66.50	gold quality
upper lobe of lung	UBERON:0008948	65.97	gold quality
tonsil	UBERON:0002372	65.89	gold quality
nasal cavity mucosa	UBERON:0001826	65.82	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	29.37
E-CURD-122	yes	24.57
E-CURD-88	yes	20.29
E-ANND-3	yes	8.07
E-MTAB-9801	yes	5.92

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
CD69	Unknown

miRNA regulators (miRDB)

71 targeting SLA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-6833-5P	99.50	68.93	1161

Literature-anchored findings (GeneRIF, showing 5)

• negatively regulates T cell receptor signaling (PMID:11891219)
• The human SLAP-2 gene is located on chromosome 20q, and the SLAP-2 coding region consists of seven exons, a unique cDNA encoding an alternatively spliced SLAP-2 isoform has been identified (PMID:12527895)
• In platelets, SLAP-2 may have function as a negative regulator of GPVI-mediated signaling by interacting with c-Cbl. (PMID:20828795)
• SLAP2 SH3 and SH2 domains are separated by a short SH3-SH2 connector sequence. (PMID:24018043)
• SLAP2 Adaptor Binding Disrupts c-CBL Autoinhibition to Activate Ubiquitin Ligase Function. (PMID:33617900)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	sla2b	ENSDARG00000020788
danio_rerio	sla2a	ENSDARG00000099887
mus_musculus	Sla2	ENSMUSG00000027636
rattus_norvegicus	Sla2	ENSRNOG00000020337
drosophila_melanogaster	dock	FBGN0010583
caenorhabditis_elegans		WBGENE00006410

Paralogs (9): DAPP1 (ENSG00000070190), NCK2 (ENSG00000071051), GRAP2 (ENSG00000100351), GRAP (ENSG00000154016), SLA (ENSG00000155926), NCK1 (ENSG00000158092), GRB2 (ENSG00000177885), GRAPL (ENSG00000189152), SH2D5 (ENSG00000189410)

Protein

Protein identifiers

Src-like-adapter 2 — Q9H6Q3 (reviewed: Q9H6Q3)

Alternative names: Modulator of antigen receptor signaling, Src-like adapter protein 2

All UniProt accessions (1): Q9H6Q3

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein, which negatively regulates T-cell receptor (TCR) signaling. Inhibits T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. May act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins.

Subunit / interactions. Interacts (via SH2 domain) with ZAP70 (phosphorylated) and CD3Z (phosphorylated). Interacts (via SH2 domain) with CSF1R (phosphorylated). Interacts (via its C-terminal domain) with CBL (phosphorylated).

Subcellular location. Cytoplasm Cell membrane. Cytoplasmic vesicle Cytoplasm.

Tissue specificity. Predominantly expressed in immune system, with highest levels in peripheral blood leukocytes. Expressed in spleen, thymus and lymph nodes. Expressed in T-cells as well as in monocytes, and at low level in B-cells. Also detected in placenta, prostate, skin, retina and colon.

Post-translational modifications. Phosphorylated by CSF1R.

Domain organisation. The loss of the C-terminal domain partially abolishes the inhibitory function, but can be partially compensated by higher level of protein expression.

Miscellaneous. Produced by alternative initiation at Met-28 of isoform 1. Produced by alternative initiation at Met-28 of isoform 2.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9H6Q3-1	1, p28	yes
Q9H6Q3-2	2, p23, SLAP-2-v, MARS-v
Q9H6Q3-3	3, p25
Q9H6Q3-4	4, p20

RefSeq proteins (2): NP_115590, NP_778252 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR001452	SH3_domain	Domain
IPR035052	SLAP_SH2	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR043539	Grb2-like	Family

Pfam: PF00017, PF00018

UniProt features (30 total): strand 12, splice variant 3, helix 3, turn 2, domain 2, region of interest 2, initiator methionine 1, chain 1, sequence variant 1, mutagenesis site 1, compositionally biased region 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4M4Z	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6Q3-F1	76.52	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Mutagenesis-validated functional residues (1):

Position	Phenotype
2	abolishes localization to membranes.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9706369	Negative regulation of FLT3
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-168256	Immune System
R-HSA-9607240	FLT3 Signaling

MSigDB gene sets: 134 (showing top): GOBP_REGULATION_OF_T_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, RACCACAR_AML_Q6, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_B_CELL_MEDIATED_IMMUNITY, GOBP_NEGATIVE_REGULATION_OF_T_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, TGCTGAY_UNKNOWN, GOBP_ADAPTIVE_IMMUNE_RESPONSE, GOBP_T_CELL_RECEPTOR_SIGNALING_PATHWAY

GO Biological Process (7): negative regulation of transcription by RNA polymerase II (GO:0000122), B cell mediated immunity (GO:0019724), T cell activation (GO:0042110), regulation of immune response (GO:0050776), negative regulation of calcium-mediated signaling (GO:0050849), antigen receptor-mediated signaling pathway (GO:0050851), negative regulation of T cell receptor signaling pathway (GO:0050860)

GO Molecular Function (2): signaling adaptor activity (GO:0035591), protein binding (GO:0005515)

GO Cellular Component (10): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), late endosome (GO:0005770), Golgi apparatus (GO:0005794), cytosol (GO:0005829), plasma membrane (GO:0005886), endosome membrane (GO:0010008), endomembrane system (GO:0012505), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
FLT3 Signaling	1
Immune System	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	3
endosome	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
lymphocyte mediated immunity	1
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	1
lymphocyte activation	1
regulation of immune system process	1
immune response	1
regulation of response to stimulus	1
calcium-mediated signaling	1
regulation of calcium-mediated signaling	1
negative regulation of intracellular signal transduction	1
immune response-activating cell surface receptor signaling pathway	1
T cell receptor signaling pathway	1
regulation of T cell receptor signaling pathway	1
negative regulation of antigen receptor-mediated signaling pathway	1
protein-macromolecule adaptor activity	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
vacuole	1
plasma membrane	1
intracellular vesicle	1

Protein interactions and networks

STRING

1292 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLA2	HIP1R	O75146	951
SLA2	TLN2	Q9Y4G6	786
SLA2	TLN1	Q9Y490	784
SLA2	SLMAP	Q14BN4	777
SLA2	HTT	P42858	736
SLA2	CLTC	Q00610	734
SLA2	SNAP91	O60641	703
SLA2	NLRP2	Q9NX02	669
SLA2	SLC29A1	Q99808	636
SLA2	CBL	P22681	623
SLA2	ZNF461	Q8TAF7	601
SLA2	EPN3	Q9H201	596
SLA2	EPN2	O95208	583
SLA2	CLTCL1	P53675	580
SLA2	FCHO1	O14526	574

IntAct

26 interactions, top by confidence:

A	B	Type	Score
PRKAA2	SLA2	psi-mi:“MI:0915”(physical association)	0.560
UBASH3A	SLA2	psi-mi:“MI:0915”(physical association)	0.560
EGFR	SLA2	psi-mi:“MI:0915”(physical association)	0.550
SLA2	EGFR	psi-mi:“MI:0915”(physical association)	0.550
MAP1LC3A	SLA2	psi-mi:“MI:0407”(direct interaction)	0.440
SLA2	ERBB2	psi-mi:“MI:0407”(direct interaction)	0.440
SLA2	GAB1	psi-mi:“MI:0407”(direct interaction)	0.440
SLA2	KIT	psi-mi:“MI:0407”(direct interaction)	0.440
SLA2	MET	psi-mi:“MI:0407”(direct interaction)	0.440
ALK	SLA2	psi-mi:“MI:0915”(physical association)	0.370
ALB	CNOT1	psi-mi:“MI:0914”(association)	0.350
SLA2	RPSA2	psi-mi:“MI:0914”(association)	0.350
PRKAA2	SLA2	psi-mi:“MI:0915”(physical association)	0.000
UBASH3A	SLA2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (39): SLA2 (Two-hybrid), SLA2 (PCA), UBASH3A (Two-hybrid), PRKAA2 (Two-hybrid), SLA2 (Reconstituted Complex), SLA2 (Reconstituted Complex), SLA2 (Reconstituted Complex), SLA2 (Reconstituted Complex), SLA2 (Reconstituted Complex), SLA2 (Reconstituted Complex), SLA2 (Reconstituted Complex), CD247 (Affinity Capture-Western), ZAP70 (Affinity Capture-Western), CBL (Affinity Capture-Western), SLA2 (Reconstituted Complex)

ESM2 similar proteins: A1A4I4, A1A5B6, A1DZY4, A4D2P6, A5D7J5, O35141, O35929, O62683, O75628, O88667, O88910, O88954, P04629, P0C7J6, P35739, P55040, P55041, P55042, P55043, P70268, Q13368, Q16512, Q3MII6, Q3UFB7, Q5E9J3, Q5EBH1, Q5R541, Q60806, Q63433, Q6IMA7, Q6IMB1, Q6P5Z2, Q7L0Q8, Q864R5, Q8IYK8, Q8K045, Q8R4L0, Q8VEL9, Q8VHP8, Q8WWW0

Diamond homologs: A0A8I3NFE2, A0JNB0, A1Y2K1, A6QLK6, B2RZ59, D7PF45, F1N9Y5, G5ECJ6, O14796, O15357, O35324, O45539, O60880, O88890, P00519, P00520, P00521, P00522, P00523, P00524, P00525, P00526, P05480, P06239, P06240, P06241, P08103, P08631, P10447, P10936, P12931, P13115, P13116, P14084, P14085, P15054, P16277, P25020, P29349, P31693

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SLA2	“down-regulates activity”	FLT3	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 12 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by Aberrant PI3K in Cancer	5	63.4×	1e-06
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	5	48.4×	3e-06
PIP3 activates AKT signaling	5	33.4×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1328 predictions. Top by Δscore:

Variant	Effect	Δscore
20:36613985:AGC:A	acceptor_loss	1.0000
20:36613986:GCTG:G	acceptor_loss	1.0000
20:36613987:C:CC	acceptor_gain	1.0000
20:36632591:TCACC:T	donor_loss	1.0000
20:36632592:CACCT:C	donor_loss	1.0000
20:36632593:A:AC	donor_gain	1.0000
20:36632594:C:CA	donor_loss	1.0000
20:36632594:C:CC	donor_gain	1.0000
20:36632594:CCT:C	donor_gain	1.0000
20:36632594:CCTCT:C	donor_gain	1.0000
20:36632695:CCAC:C	acceptor_gain	1.0000
20:36632696:CAC:C	acceptor_gain	1.0000
20:36632696:CACC:C	acceptor_gain	1.0000
20:36632699:C:T	acceptor_loss	1.0000
20:36632700:T:G	acceptor_loss	1.0000
20:36632703:C:CT	acceptor_gain	1.0000
20:36632708:C:CT	acceptor_gain	1.0000
20:36632709:G:T	acceptor_gain	1.0000
20:36633541:A:AC	donor_gain	1.0000
20:36633542:C:CC	donor_gain	1.0000
20:36633627:TCC:T	acceptor_gain	1.0000
20:36633628:CC:C	acceptor_gain	1.0000
20:36633628:CCC:C	acceptor_gain	1.0000
20:36633629:CC:C	acceptor_gain	1.0000
20:36633630:CTG:C	acceptor_loss	1.0000
20:36633631:T:A	acceptor_loss	1.0000
20:36634488:A:AC	donor_gain	1.0000
20:36634489:C:CC	donor_gain	1.0000
20:36634489:CT:C	donor_gain	1.0000
20:36613843:C:A	donor_gain	0.9900

AlphaMissense

1668 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:36632623:G:C	F118L	0.997
20:36632623:G:T	F118L	0.997
20:36632625:A:G	F118L	0.997
20:36615308:A:G	I150T	0.995
20:36615259:G:C	F166L	0.993
20:36615259:G:T	F166L	0.993
20:36615261:A:G	F166L	0.993
20:36615356:A:T	V134D	0.992
20:36632618:A:T	I120N	0.992
20:36615308:A:C	I150S	0.991
20:36632621:A:G	L119P	0.990
20:36632667:C:G	A104P	0.990
20:36632697:A:G	W94R	0.990
20:36632697:A:T	W94R	0.990
20:36615242:A:G	L172P	0.989
20:36615308:A:T	I150N	0.989
20:36632615:C:G	R121P	0.989
20:36615362:A:G	L132P	0.988
20:36614410:A:T	L187H	0.987
20:36632624:A:G	F118S	0.986
20:36615360:A:G	S133P	0.984
20:36615278:A:T	I160N	0.982
20:36615316:G:C	H147Q	0.982
20:36615316:G:T	H147Q	0.982
20:36615318:G:C	H147D	0.982
20:36632657:A:G	L107P	0.982
20:36632618:A:C	I120S	0.980
20:36632618:A:G	I120T	0.980
20:36632654:A:G	L108P	0.980
20:36615260:A:G	F166S	0.979

dbSNP variants (sampled 300 via entrez): RS1000035800 (20:36632176 T>C), RS1000107951 (20:36646966 T>A), RS1000234798 (20:36616039 A>G), RS1000261678 (20:36615044 C>T), RS1000295455 (20:36628700 C>T), RS1000480803 (20:36648001 C>T), RS1000718446 (20:36635047 G>A), RS1000788125 (20:36628149 C>G), RS1000795194 (20:36635277 C>G,T), RS1000811777 (20:36635259 A>G), RS1000863554 (20:36616254 A>G), RS1000888147 (20:36642206 G>C), RS1000948205 (20:36628461 A>T), RS1001140349 (20:36642362 C>A), RS1001197322 (20:36621198 C>T)

Disease associations

OMIM: gene MIM:606577 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	2
aristolochic acid I	increases expression	1
OTX015	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Arsenic Trioxide	increases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	increases phosphorylation	1
Calcitriol	increases expression, affects cotreatment	1
Mercuric Chloride	affects cotreatment, increases expression	1
Nickel	increases expression	1
Testosterone	increases expression, affects cotreatment	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.